JP2011506463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506463A5 JP2011506463A5 JP2010538112A JP2010538112A JP2011506463A5 JP 2011506463 A5 JP2011506463 A5 JP 2011506463A5 JP 2010538112 A JP2010538112 A JP 2010538112A JP 2010538112 A JP2010538112 A JP 2010538112A JP 2011506463 A5 JP2011506463 A5 JP 2011506463A5
- Authority
- JP
- Japan
- Prior art keywords
- naphthalen
- ylamino
- tetrahydro
- diethyl
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 63
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 239000002623 mu opiate receptor antagonist Substances 0.000 claims description 5
- 206010054048 Postoperative ileus Diseases 0.000 claims description 4
- 230000001668 ameliorated effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 229940124636 opioid drug Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- HYECURROVNFJPR-NKKJXINNSA-N (2r)-2-(cyclohexylmethyl)-4-[[(2s,3s)-1,1-diethyl-7-hydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]butanoic acid Chemical compound C([C@H](CCN[C@H]1C(C2=CC(O)=CC=C2C[C@@H]1OC)(CC)CC)C(O)=O)C1CCCCC1 HYECURROVNFJPR-NKKJXINNSA-N 0.000 claims description 2
- VSPBOZJQHZHHQJ-YZGWKJHDSA-N (2r)-2-[2-[[(2s,3s)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]ethyl]-3-methylbutanoic acid Chemical compound C1=C(C(N)=O)C=C2C(CC)(CC)[C@H](NCC[C@H](C(C)C)C(O)=O)[C@@H](OC)CC2=C1 VSPBOZJQHZHHQJ-YZGWKJHDSA-N 0.000 claims description 2
- CWUCVIBRYFCEMZ-SESVDKBCSA-N (2r)-2-[2-[[(2s,3s)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]ethyl]-4,4-dimethylpentanoic acid Chemical compound C1=C(C(N)=O)C=C2C(CC)(CC)[C@H](NCC[C@@H](CC(C)(C)C)C(O)=O)[C@@H](OC)CC2=C1 CWUCVIBRYFCEMZ-SESVDKBCSA-N 0.000 claims description 2
- LWFVSHOPLHLEQG-TYCQWZJGSA-N (2r)-2-[2-[[(2s,3s)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]ethyl]hexanoic acid Chemical compound C1=C(C(N)=O)C=C2C(CC)(CC)[C@H](NCC[C@@H](CCCC)C(O)=O)[C@@H](OC)CC2=C1 LWFVSHOPLHLEQG-TYCQWZJGSA-N 0.000 claims description 2
- AMMHQMIASWQZNQ-QTJGBDASSA-N (2r)-4-[[(2r,3r)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]-2-(cyclohexylmethyl)butanoic acid Chemical compound C([C@H](CCN[C@@H]1C(C2=CC(=CC=C2C[C@H]1OC)C(N)=O)(CC)CC)C(O)=O)C1CCCCC1 AMMHQMIASWQZNQ-QTJGBDASSA-N 0.000 claims description 2
- AMMHQMIASWQZNQ-OEMFJLHTSA-N (2r)-4-[[(2s,3s)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]-2-(cyclohexylmethyl)butanoic acid Chemical compound C([C@H](CCN[C@H]1C(C2=CC(=CC=C2C[C@@H]1OC)C(N)=O)(CC)CC)C(O)=O)C1CCCCC1 AMMHQMIASWQZNQ-OEMFJLHTSA-N 0.000 claims description 2
- HYECURROVNFJPR-HUVFLSCGSA-N (2s)-2-(cyclohexylmethyl)-4-[[(2r,3r)-1,1-diethyl-7-hydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]butanoic acid Chemical compound C([C@@H](CCN[C@@H]1C(C2=CC(O)=CC=C2C[C@H]1OC)(CC)CC)C(O)=O)C1CCCCC1 HYECURROVNFJPR-HUVFLSCGSA-N 0.000 claims description 2
- HYECURROVNFJPR-FGCOXFRFSA-N (2s)-2-(cyclohexylmethyl)-4-[[(2s,3s)-1,1-diethyl-7-hydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]butanoic acid Chemical compound C([C@@H](CCN[C@H]1C(C2=CC(O)=CC=C2C[C@@H]1OC)(CC)CC)C(O)=O)C1CCCCC1 HYECURROVNFJPR-FGCOXFRFSA-N 0.000 claims description 2
- CWUCVIBRYFCEMZ-HLAWJBBLSA-N (2s)-2-[2-[[(2s,3s)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]ethyl]-4,4-dimethylpentanoic acid Chemical compound C1=C(C(N)=O)C=C2C(CC)(CC)[C@H](NCC[C@H](CC(C)(C)C)C(O)=O)[C@@H](OC)CC2=C1 CWUCVIBRYFCEMZ-HLAWJBBLSA-N 0.000 claims description 2
- QSSVAMLYKVFNKL-HLAWJBBLSA-N (2s)-2-[2-[[(2s,3s)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]ethyl]-4-methylpentanoic acid Chemical compound C1=C(C(N)=O)C=C2C(CC)(CC)[C@H](NCC[C@H](CC(C)C)C(O)=O)[C@@H](OC)CC2=C1 QSSVAMLYKVFNKL-HLAWJBBLSA-N 0.000 claims description 2
- CSBRXZYLNZBZGM-OUIFVKKZSA-N (2s)-2-[2-[[(2s,3s)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]ethyl]-5-phenylpentanoic acid Chemical compound C([C@@H](CCN[C@H]1C(C2=CC(=CC=C2C[C@@H]1OC)C(N)=O)(CC)CC)C(O)=O)CCC1=CC=CC=C1 CSBRXZYLNZBZGM-OUIFVKKZSA-N 0.000 claims description 2
- KLLDHTUHRKLVBO-BULFRSBZSA-N (2s)-2-[2-[[(2s,3s)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]ethyl]heptanoic acid Chemical compound C1=C(C(N)=O)C=C2C(CC)(CC)[C@H](NCC[C@H](CCCCC)C(O)=O)[C@@H](OC)CC2=C1 KLLDHTUHRKLVBO-BULFRSBZSA-N 0.000 claims description 2
- XGVFTDUSJJZTDB-YFNKSVMNSA-N (2s)-2-benzyl-4-[[(2s,3s)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]butanoic acid Chemical compound C([C@@H](CCN[C@H]1C(C2=CC(=CC=C2C[C@@H]1OC)C(N)=O)(CC)CC)C(O)=O)C1=CC=CC=C1 XGVFTDUSJJZTDB-YFNKSVMNSA-N 0.000 claims description 2
- AMMHQMIASWQZNQ-JRFVFWCSSA-N (2s)-4-[[(2r,3r)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]-2-(cyclohexylmethyl)butanoic acid Chemical compound C([C@@H](CCN[C@@H]1C(C2=CC(=CC=C2C[C@H]1OC)C(N)=O)(CC)CC)C(O)=O)C1CCCCC1 AMMHQMIASWQZNQ-JRFVFWCSSA-N 0.000 claims description 2
- AMMHQMIASWQZNQ-YFNKSVMNSA-N (2s)-4-[[(2s,3s)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]-2-(cyclohexylmethyl)butanoic acid Chemical compound C([C@@H](CCN[C@H]1C(C2=CC(=CC=C2C[C@@H]1OC)C(N)=O)(CC)CC)C(O)=O)C1CCCCC1 AMMHQMIASWQZNQ-YFNKSVMNSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- BDCUNDDRSKEYHX-BAGYTPMASA-N methyl (2s)-2-[2-[[(2s,3s)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]ethyl]-4-methylpentanoate Chemical compound C1=C(C(N)=O)C=C2C(CC)(CC)[C@H](NCC[C@H](CC(C)C)C(=O)OC)[C@@H](OC)CC2=C1 BDCUNDDRSKEYHX-BAGYTPMASA-N 0.000 claims description 2
- CZLIXMJRYLALKR-GPXOXTDOSA-N methyl (2s)-4-[[(2r,3r)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]-2-(cyclohexylmethyl)butanoate Chemical compound C([C@@H](CCN[C@@H]1C(C2=CC(=CC=C2C[C@H]1OC)C(N)=O)(CC)CC)C(=O)OC)C1CCCCC1 CZLIXMJRYLALKR-GPXOXTDOSA-N 0.000 claims description 2
- CZLIXMJRYLALKR-PZUNEJSGSA-N methyl (2s)-4-[[(2s,3s)-7-carbamoyl-1,1-diethyl-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]-2-(cyclohexylmethyl)butanoate Chemical compound C([C@@H](CCN[C@H]1C(C2=CC(=CC=C2C[C@@H]1OC)C(N)=O)(CC)CC)C(=O)OC)C1CCCCC1 CZLIXMJRYLALKR-PZUNEJSGSA-N 0.000 claims description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 claims description 2
- 239000000014 opioid analgesic Substances 0.000 claims description 2
- 239000003444 phase transfer catalyst Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000010998 test method Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 108020001612 μ-opioid receptors Proteins 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- HYECURROVNFJPR-ZTCOLXNVSA-N (2r)-2-(cyclohexylmethyl)-4-[[(2r,3r)-1,1-diethyl-7-hydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-2-yl]amino]butanoic acid Chemical compound C([C@H](CCN[C@@H]1C(C2=CC(O)=CC=C2C[C@H]1OC)(CC)CC)C(O)=O)C1CCCCC1 HYECURROVNFJPR-ZTCOLXNVSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US722007P | 2007-12-11 | 2007-12-11 | |
| US61/007,220 | 2007-12-11 | ||
| US4921908P | 2008-04-30 | 2008-04-30 | |
| US61/049,219 | 2008-04-30 | ||
| PCT/US2008/086171 WO2009076408A2 (en) | 2007-12-11 | 2008-12-10 | 3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011506463A JP2011506463A (ja) | 2011-03-03 |
| JP2011506463A5 true JP2011506463A5 (enExample) | 2012-11-08 |
| JP5403762B2 JP5403762B2 (ja) | 2014-01-29 |
Family
ID=40521484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538112A Expired - Fee Related JP5403762B2 (ja) | 2007-12-11 | 2008-12-10 | μオピオイド受容体アンタゴニストとしての３−カルボキシプロピル−アミノテトラリン誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US8106232B2 (enExample) |
| EP (1) | EP2231585B1 (enExample) |
| JP (1) | JP5403762B2 (enExample) |
| KR (1) | KR101610165B1 (enExample) |
| CN (1) | CN101896455B (enExample) |
| AR (1) | AR072336A1 (enExample) |
| AU (1) | AU2008335210B2 (enExample) |
| BR (1) | BRPI0821611A8 (enExample) |
| CA (1) | CA2707981C (enExample) |
| CL (1) | CL2008003672A1 (enExample) |
| CO (1) | CO6300937A2 (enExample) |
| ES (1) | ES2402749T3 (enExample) |
| IL (1) | IL205949A (enExample) |
| MY (1) | MY149973A (enExample) |
| NZ (1) | NZ586048A (enExample) |
| RU (1) | RU2482107C2 (enExample) |
| TW (1) | TWI412360B (enExample) |
| WO (1) | WO2009076408A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| EP3020706A1 (en) | 2006-03-29 | 2016-05-18 | The Regents Of The University Of California | Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder |
| EP2220050A2 (en) | 2007-10-26 | 2010-08-25 | The Regents Of The University Of California | Diarylhydantoin compounds as androgen receptor modulators |
| US8101791B2 (en) | 2007-12-11 | 2012-01-24 | Theravance, Inc. | Aminotetralin compounds as mu opioid receptor antagonists |
| EP2280933B1 (en) * | 2008-04-01 | 2013-07-24 | Theravance, Inc. | 2 -aminotetralin derivatives as mu opioid receptor antagonists |
| JP5650657B2 (ja) | 2008-12-10 | 2015-01-07 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ３−カルボキシプロピル−アミノテトラリン化合物の結晶形態 |
| MX342548B (es) * | 2009-09-18 | 2016-10-04 | Merck Sharp & Dohme Corp * | Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2051399C (en) * | 1989-05-31 | 2003-12-30 | Chiu-Hong Lin | Therapeutically useful 2-aminotetralin derivatives |
| WO2000037426A1 (en) * | 1998-12-22 | 2000-06-29 | Astrazeneca Ab | Novel oxo-aminotetralin compounds useful in pain management |
| AU3092800A (en) * | 1998-12-22 | 2000-07-12 | Astra Pharma Inc. | Novel thio-aminotetralin compounds useful in pain management |
| US6498196B1 (en) * | 1998-12-22 | 2002-12-24 | Edward Roberts | Compounds useful in pain management |
| US6844368B1 (en) * | 1998-12-22 | 2005-01-18 | Edward Roberts | Compounds useful in pain management |
| US6231594B1 (en) * | 1999-08-11 | 2001-05-15 | Radiant Medical, Inc. | Method of controlling body temperature while reducing shivering |
| JP2010509227A (ja) | 2006-11-07 | 2010-03-25 | ネクター セラピューティックス エイエル，コーポレイション | オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与 |
| US8101791B2 (en) * | 2007-12-11 | 2012-01-24 | Theravance, Inc. | Aminotetralin compounds as mu opioid receptor antagonists |
| EP2280933B1 (en) | 2008-04-01 | 2013-07-24 | Theravance, Inc. | 2 -aminotetralin derivatives as mu opioid receptor antagonists |
| JP5650657B2 (ja) | 2008-12-10 | 2015-01-07 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ３−カルボキシプロピル−アミノテトラリン化合物の結晶形態 |
-
2008
- 2008-12-10 MY MYPI2010002437A patent/MY149973A/en unknown
- 2008-12-10 BR BRPI0821611A patent/BRPI0821611A8/pt not_active Application Discontinuation
- 2008-12-10 CN CN200880119873.7A patent/CN101896455B/zh not_active Expired - Fee Related
- 2008-12-10 EP EP08859864A patent/EP2231585B1/en not_active Not-in-force
- 2008-12-10 NZ NZ586048A patent/NZ586048A/en not_active IP Right Cessation
- 2008-12-10 ES ES08859864T patent/ES2402749T3/es active Active
- 2008-12-10 KR KR1020107014774A patent/KR101610165B1/ko not_active Expired - Fee Related
- 2008-12-10 RU RU2010128542/04A patent/RU2482107C2/ru active
- 2008-12-10 US US12/331,659 patent/US8106232B2/en not_active Expired - Fee Related
- 2008-12-10 CL CL2008003672A patent/CL2008003672A1/es unknown
- 2008-12-10 JP JP2010538112A patent/JP5403762B2/ja not_active Expired - Fee Related
- 2008-12-10 CA CA2707981A patent/CA2707981C/en active Active
- 2008-12-10 TW TW097148045A patent/TWI412360B/zh not_active IP Right Cessation
- 2008-12-10 WO PCT/US2008/086171 patent/WO2009076408A2/en not_active Ceased
- 2008-12-10 AR ARP080105365A patent/AR072336A1/es unknown
- 2008-12-10 AU AU2008335210A patent/AU2008335210B2/en not_active Ceased
-
2010
- 2010-05-25 IL IL205949A patent/IL205949A/en active IP Right Grant
- 2010-06-11 CO CO10070802A patent/CO6300937A2/es not_active Application Discontinuation
-
2011
- 2011-12-19 US US13/330,363 patent/US8318765B2/en not_active Expired - Fee Related
-
2012
- 2012-10-16 US US13/652,808 patent/US8492399B2/en not_active Expired - Fee Related
-
2013
- 2013-06-19 US US13/921,448 patent/US8703791B2/en active Active
-
2014
- 2014-03-04 US US14/196,186 patent/US8969370B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506463A5 (enExample) | ||
| WO2008044656A1 (fr) | Dérivé d'imidazolidinone | |
| US9073874B2 (en) | Cyclic N,N′-diarylthioureas and N,N′-diarylureas-androgen receptor antagonists, anticancer agent, method for preparation and use thereof | |
| JP2012524108A (ja) | モノアミン再取り込み阻害剤 | |
| AU2020239746B2 (en) | Compositions comprising methylphenidate-prodrugs, processes of making and using the same | |
| TWI698415B (zh) | 胺基羰基胺基甲酸酯化合物 | |
| JP2007515447A5 (enExample) | ||
| JP2017132802A (ja) | ヒストンアセチルトランスフェラーゼ活性剤の使用 | |
| RU2010128542A (ru) | Производные 3-карбоксипропил-аминотетралина и родственные соединения в качестве антагонистов mu-опиоидного рецептора | |
| EP4405318A1 (en) | Substituted phenylalkylamines | |
| JP2013508384A (ja) | アルファアドレナリン受容体モジュレーター | |
| US20230373940A1 (en) | Carboxylic diarylthiazepineamines and uses thereof | |
| JP2014503601A (ja) | フェニル−イソオキサゾール誘導体およびその製造方法 | |
| US9463187B2 (en) | Methylphenidate derivatives and uses of them | |
| JP5253155B2 (ja) | 肥満治療に有用なｍａｏ−ｂ阻害剤 | |
| AU2015369903B2 (en) | Compounds, compositions and methods | |
| EP2475361B1 (en) | N-substituted benzenepropanamides for use in the treatment of pain and inflammation | |
| RU2011139287A (ru) | Оксииндольные производные, обладающие агонистической активностью в отношении мотилинового рецептора | |
| JP2007536318A5 (enExample) | ||
| JP2008540618A5 (enExample) | ||
| WO2015046405A1 (ja) | 鎮痛剤 | |
| US12357610B2 (en) | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | |
| US8329741B2 (en) | Substituted pyrrolidine compounds with central nervous system activity | |
| RU2790360C2 (ru) | Аминокарбонилкарбаматные соединения | |
| KR20250020444A (ko) | 아제티딘 화합물, 그의 약학 조성물, 제조 방법 및 중추신경계 질환 치료에서의 그의 용도 |